Absci Corp
Business
Absci Corp is a clinical-stage biopharmaceutical company developing differentiated antibody therapeutics using an AI-native approach combining generative design models with lab-in-the-loop validation. The company's Integrated Drug Creation platform leverages proprietary AI models, including Origin-1 for de novo antibody design, to identify and optimize therapeutics against underexplored biological targets. Absci is advancing ABS-201, an anti-prolactin receptor antibody in clinical trials for androgenetic alopecia and endometriosis, alongside preclinical programs in oncology and inflammation, while also partnering with pharmaceutical companies for drug creation collaborations and potential out-licensing arrangements.
Summary from 10-K filed 2026-03-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Partner program revenue | 3 | 5 | 6 | 5 | 4 | |
| Research and development | 81 | 64 | 48 | 59 | 45 | |
| Selling, general and administrative | 35 | 36 | 38 | 41 | 29 | |
| Depreciation and amortization | 12 | 13 | 14 | 13 | 7 | |
| Gain on settlement of contingent consideration | −5 | 0 | — | — | — | |
| Total operating expenses | 123 | 113 | 121 | 112 | 80 | |
| Operating loss | −120 | −109 | −116 | −107 | −75 | |
| Interest expense | −209,000 | −565,000 | −1 | — | — | |
| Other income, net | 5 | 6 | 6 | 2 | −31 | |
| Total other income, net | 5 | 6 | 5 | 1 | −35 | |
| Loss before income taxes | −115 | −103 | −110 | −105 | −110 | |
| Income tax expense | −69,000 | −70,000 | −100,000 | 461,000 | 9 | |
| Net loss | −115 | −103 | −111 | −105 | −101 | |
| Net loss per share: basic (in usd per share) | −0.84 | −0.94 | −1.2 | −1.15 | −2.08 | |
| Net loss per share: diluted (in usd per share) | −0.84 | −0.94 | −1.2 | −1.15 | −2.08 | |
| Weighted-average common shares outstanding: basic (in shares) | 137 | 110 | 92 | 91 | 50 | |
| Weighted-average common shares outstanding: diluted (in shares) | 137 | 110 | 92 | 91 | 50 | |
| Foreign currency translation adjustments | 448,000 | −26,000 | 40,000 | −66,000 | −13,000 | |
| Unrealized gain on marketable securities | 147,000 | 59,000 | 43,000 | −41,000 | 0 | |
| Comprehensive loss | −115 | −103 | −110 | −105 | −101 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 20 | 41 | 72 | 60 | 253 | |
| Restricted cash | 0 | 16 | 16 | 15 | 11 | |
| Marketable securities | 124 | 71 | — | — | — | |
| Prepaid expenses and other current assets | 5 | 5 | 5 | 6 | 9 | |
| Total current assets | 150 | 134 | 121 | 187 | 273 | |
| Operating lease right-of-use assets | 3 | 4 | 4 | 5 | 7 | |
| Property and equipment, net | 21 | 29 | 41 | 53 | 52 | |
| Intangibles, net | 42 | 45 | 48 | 52 | 55 | |
| Restricted cash, long-term | 1 | 1 | 1 | 2 | 17 | |
| Other long-term assets | 383,000 | 705,000 | 2 | 1 | 1 | |
| TOTAL ASSETS | 216 | 214 | 217 | 321 | 426 | |
| Accounts payable and accrued expenses | 19 | 10 | — | — | — | |
| Contingent consideration | 0 | 13 | 13 | — | — | |
| Long-term debt | 873,000 | 3 | 3 | 3 | 2 | |
| Operating lease obligations | 2 | 2 | 2 | 2 | 2 | |
| Deferred revenue | 739,000 | 1 | 3 | 445,000 | 1 | |
| Total current liabilities | 23 | 29 | 30 | 30 | 34 | |
| Long-term debt, net of current portion | 0 | 1 | 5 | 8 | 1 | |
| Operating lease obligations, net of current portion | 3 | 4 | 6 | 7 | 9 | |
| Deferred revenue, long-term | 436,000 | 0 | 966,000 | 0 | — | |
| Other long-term liabilities | 1 | 133,000 | 295,000 | 35,000 | 12 | |
| TOTAL LIABILITIES | 27 | 34 | 41 | 47 | 60 | |
| Commitments (See Note 11) | — | — | — | — | — | |
| Preferred stock | 0 | 0 | 0 | 0 | 0 | |
| Common stock | 15,000 | 12,000 | 9,000 | 9,000 | 9,000 | |
| Additional paid-in capital | 814 | 689 | 583 | 570 | 557 | |
| Accumulated deficit | −625 | −510 | −406 | −296 | −191 | |
| Accumulated other comprehensive income (loss) | 591,000 | −4,000 | −37,000 | −120,000 | −13,000 | |
| TOTAL STOCKHOLDERS' EQUITY | 189 | 179 | 176 | 274 | 366 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 216 | 214 | 217 | 321 | 426 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 18 | 19 | 11 | 13 | 11 | |
| Accretion of discount on marketable securities | −3 | −4 | −3 | −688,000 | 0 | |
| Gain on settlement of contingent consideration | −5 | 0 | — | — | — | |
| Other | −584,000 | 2 | 334,000 | 721,000 | 301,000 | |
| Accounts receivable, net | 0 | 2 | −666,000 | — | — | |
| Prepaid expenses and other current assets | −424,000 | −484,000 | 2 | 2 | −8 | |
| Operating lease right-of-use assets and liabilities | −555,000 | −762,000 | −856,000 | −640,000 | 3 | |
| Other long-term assets | 249,000 | −68,000 | −255,000 | 13,000 | 126,000 | |
| Accounts payable and accrued expenses | 1 | 2 | −786,000 | −533,000 | 2 | |
| Deferred revenue | 59,000 | −3 | 4 | −907,000 | −1 | |
| Net cash used in operating activities | −93 | −72 | −65 | −81 | −61 | |
| Purchases of property and equipment | −1 | −404,000 | −860,000 | −16 | −38 | |
| Investment in marketable securities | −120 | −186 | −147 | −109 | 0 | |
| Proceeds from maturities of marketable securities | 70 | 144 | 230 | 5 | 0 | |
| Proceeds from sales of property and equipment | 1 | 939,000 | 254,000 | 133,000 | 0 | |
| Net cash used in investing activities | −50 | −42 | 82 | −127 | −67 | |
| Principal payments on long-term debt | −3 | −3 | −3 | −5 | −2 | |
| Principal payments on finance lease obligations | −79,000 | −643,000 | −2 | −3 | −3 | |
| Proceeds from issuance of common stock, net | 106 | 82 | 862,000 | 656,000 | 210 | |
| Proceeds from issuance of common stock through employee equity plans, net | 3 | 4 | 862,000 | — | — | |
| Net cash provided by financing activities | 106 | 83 | −4 | 5 | 336 | |
| Net decrease in cash, cash equivalents, and restricted cash | −37 | −31 | 13 | −203 | 208 | |
| Cash paid during the period for interest | 178,000 | 561,000 | 970,000 | 895,000 | 652,000 | |
| Right-of-use assets obtained in exchange for operating lease obligation | 0 | 433,000 | 0 | 111,000 | 3 | |
| Payments on long-term debt by third-party through sale of equipment | 0 | 540,000 | 0 | 123,000 | 6 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Absci Corp's CIK number?
Absci Corp's SEC CIK number is 0001672688 (1672688). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Absci Corp's SEC filings?
All of Absci Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Absci Corp last report earnings?
Absci Corp (ABSI) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001672688-26-000086). This is Absci Corp's most recent earnings filing of record — not a forecast of its next earnings date.
What is Absci Corp's most recent earnings 8-K?
Absci Corp's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001672688-26-000086. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Absci Corp's latest earnings 8-K →
Look up any company's CIK number →